[13] Emens L A, Cruz C, Eder J P, et al. Long-term Clinical Outcomes andBiomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study[J]. JAMA Oncol,2019,5(1):74-82.
[14] Bosma SC, van der Leij F, van Werkhoven E, et al. Very lowlocalrecurrence rates after breast-conserving therapy: analysis of 8485 patients treatedover a 28-year period[J]. Breast Cancer Res Treat,2016, 156(2): 391-400.
[15] van Maaren MC, de Munck L, Jobsen JJ, et al. Breast-conserving therapyversus mastectomy in T1-2N2 stage breast cancer: a population-based study on10-year overall, relative, and distant metastasis-free survival in 3071 patients[J].Breast Cancer Res Treat, 2016, 160(3): 511-21.
[16] Chinese anti-cancer association, Committee of breast cancer society.Guideline and Standard for the diagnosis and treatment of breast cancer by ChineseAnti-cancer Association(2017edition)[J]. Zhongguo Ai Zheng Za Zhi, 2017, 27(9): 695-760.